TPX-02226

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTPX-02226

Drug Alias NameN/A

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionTyrosine-protein kinase SRC inhibitorsHepatocyte growth factor receptor inhibitorsProto-oncogene serine/threonine-protein kinase Pim-1 inhibitors

TargetsTyrosine-protein kinase SRCHepatocyte growth factor receptorProto-oncogene serine/threonine-protein kinase Pim-1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTurning Point Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesTurning Point Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A